The Federal Circuit reversed and remanded the decision of the District of Delaware that claims of REGENXBIO Inc. and The Trustees of the University of Pennsylvania’s patent directed to genetically engineered host cells that contain adeno-associated virus rh.10 sequences are unpatentable, in this infringement action against Sarepta Therapeutics Inc. and Sarepta Therapeutics Three LLC. The appeals court determined that the claims aren’t directed to a natural phenomenon.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.